24 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Ranbaxy Laboratories is contemplating on slashing its global sales staff by about a third, with a majority of the job cuts expected to be in the US, according to a report by Business Standard. Ranbaxy's current global field force stands at around 14,600.
Ranbaxy has been surrounded by controversy since early last week when it pleaded guilty to making false statements to the US FDA about how two of its Indian plants tested drugs. The firm was asked to pay $500 million as penalty, which makes this the the largest false-claims case involving a generics drugs maker in the US.